Onkológia 5/2010
Adjuvant therapy of bladder cancer
Optimal integration of treatment modalities with radical cystectomy as well as in organ preserving treatment of muscle-invasive bladder cancer remains unknown. Systemic cisplatin-based combined chemotherapy is the only current modality that has been shown to improve overall survival. Main problems in optimization of adjuvant therapies, particularly patient selection, toxicity and equivocal interpretation of clinical evidence are discussed.
Keywords: bladder cancer, neoadjuvant chemotherapy, adjuvant chemotherapy, radiotherapy, bladder preserving treatment.
